The data showed that KRAS status did not affect the efficacy of nivolumab in NSCLC, and TP53 co-mutated NSCLC patients also showed significant and durable clinical benefits from anti-PD-1 therapy, while patients with LKB1/STK11 tumor suppressor gene co-mutations were associated with shorter PFS and OS, possibly suggesting that LKB1 deficiency is a major driver of immune escape and a genomic biomarker of innate resistance to ICIs [25]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.